Latest market data
| Close | 46.9 (-1.59% on the day; -2.74% over 5 sessions; -1.01% over 20 sessions) |
|---|---|
| Market cap | CNY 311.28 billion |
| P/E (TTM) | 35.04x (1th percentile over 5.2 years) |
| P/B (MRQ) | 4.66x (2th percentile over 5.2 years) |
| P/S (TTM) | 9.48x (10th percentile over 5.2 years) |
| 52-week range | 41.89 (2026-09-11) – 65.63 (2026-01-13) |
| Moving averages | MA5 47.72 / MA10 48.52 / MA20 48.16 / MA60 46.69 |
| MACD (12,26,9) | DIF 0.237, DEA 0.492, histogram -0.511 |
| RSI | RSI6 26.4 / RSI14 44.1 |
| Bollinger bands (20,2) | Upper 50.65 / middle 48.16 / lower 45.68 |
| Volume | 0.8x the 20-day average |
| One-week range (about 68% coverage) | 44.91 – 48.2 (-4.2% ~ +2.8%) |
| One-week range (about 95% coverage) | 43.24 – 49.8 (-7.8% ~ +6.2%) |
As of the 2026-11-18 close; calculated from daily price data (adjusted prices) and refreshed automatically each trading day. The one-week range reflects historical volatility only and is not a forecast. The report below was written on 2026-10-04; its prices and short-term scenarios reflect data at that time.
Jiangsu Hengrui Pharmaceuticals (600276)
Equity Research Report | Sector: Innovative Drugs & Integrated Pharmaceuticals | Report Date: October 4, 2026 | Market Data as of 2026-09-30 Close
This report is automatically compiled and generated by AI based on public information, for reference only, and does not constitute investment advice.
Core Conclusion: Innovative drug growth remains, but weakening non-recurring profit in H1 makes the earnings recovery expectation yet to be realized
| Key Data | Value |
|---|---|
| Closing Price (Daily Change) | RMB 47.20 (+3.46%) |
| Total Market Cap | Approximately RMB 313.276 billion |
| PE(TTM) | 40.55x |
| PB(MRQ) | 4.86x |
| 52-Week Range | RMB 41.89–72.92 |
| Turnover / Turnover Rate | RMB 5.235 billion / 1.76% |
Market data as of: 2026-09-30 Close
1. Key Investment Points
- Core business non-recurring profit has weakened significantly: In H1 2026, revenue declined 1.94% YoY and non-recurring net profit declined 12.71% YoY; in the corresponding single quarter, non-recurring profit fell 35.37% YoY, and the slight increase in net profit attributable to parent did not reflect the core business trend.
- Innovative drug volume ramp-up is the core of future growth: In 2025, innovative drug sales revenue grew 26.09% YoY; in H1 2026, innovative drug revenue grew 16.38%, but the sales contribution from newly approved indications remains to be verified.
- Valuation percentile is low but absolute PE remains high: Closing price on September 30 was RMB 47.20, with PE-TTM 40.55x and PB-MRQ 4.86x; these stand at the 6th and 2nd percentiles over the past 5.2 years, respectively, and the target price range from 10 institutions is RMB 50–87.42.
Market Expectations and Evidence
- What the market is pricing: Consensus net profit growth for 2026–2028 is 20.5%, 16.0%, and 19.6%, respectively; the current price implies a required 10-year EPS CAGR of approximately 19.3%. The metrics and time horizons differ, so they cannot be directly compared.
- What the evidence shows: Consensus points to earnings growth, but H1 revenue declined, non-recurring profit fell, and the single-quarter non-recurring decline widened; innovative drug revenue still grew 16.38%, and the key is whether new products can translate into improved core business profitability.
Evidence bias: Bearish; Confidence: High (key financial figures have been verified against official original text)
The weakening trend in H1 non-recurring profit and the single-quarter trend is relatively clear, but innovative drug revenue continues to grow, and the contribution from new products remains to be verified.
2. Business and Competitiveness
2.1 Business Structure
The company researches, develops, manufactures, and sells pharmaceuticals to medical institutions and pharmacies through distributors, while also obtaining upfront payments and milestone revenue through outbound licensing.
| Business Segment | Revenue Share | Gross Margin | Revenue Growth | Key Points |
|---|---|---|---|---|
| Oncology | 52.7% (2025, of total operating revenue) | 93.48% | 14.29% | Largest sales segment, carrying important innovative drug products. |
| Neuroscience | 13.6% (2025, of total operating revenue) | 82.73% | 0.07% | Revenue essentially flat, with cost growth outpacing revenue. |
| Outbound Licensing | 10.7% (2025, of total operating revenue) | — | — | Revenue recognized according to contractual performance obligations, with significant annual volatility. |
| Contrast Agents | 9.5% (2025, of total operating revenue) | 58.75% | 8.87% | Cost growth outpacing revenue, with gross margin lower than major innovative drug segments. |
| Metabolism and Cardiovascular | 7.7% (2025, of total operating revenue) | 73.69% | 39.39% | Multiple products ramping up, with cost growth outpacing revenue. |
| Immunology and Respiratory | 2.7% (2025, of total operating revenue) | 84.62% | 10.94% | Gross margin increased 0.93 percentage points YoY. |
2.2 Competitive Advantages
Competitive Advantage Strength: Medium
- R&D investment of RMB 8.724 billion, accounting for 27.58% of revenue; 5,684 R&D personnel at year-end.
- The company disclosed that 24 Class 1 innovative drugs have been approved for marketing in China, and innovative drug sales revenue grew 26.09% YoY.
- Sales and market access systems and distribution networks support commercialization; oncology segment revenue was RMB 16.671 billion.
Main threats: same-target competition, medical insurance negotiations and centralized procurement price pressure, as well as R&D failure, hospital access, and overseas registration falling short of expectations.
2.3 Industry Chain Position and Profit Trends
- Manufacturing costs include raw materials and packaging, labor, and manufacturing overhead; raw materials and packaging account for 62.92% of manufacturing costs and are not broken down by specific materials.
- In 2025, the top five suppliers accounted for 26.61% of total procurement; the annual report does not show that the company generally has upstream raw material and excipient pricing power.
- Drugs are mainly supplied to hospitals, other medical institutions, and pharmacies through distributors; in 2025, the top five customers accounted for 55.72% of annual total sales, with customer details not disclosed.
- Medical insurance negotiations, centralized procurement, tendering, and hospital access constrain drug prices; payment catalog and coverage expansion may come with price or expense pressure.
- The 2025 annual report disclosed that the top five customers accounted for 55.72% of sales, with customer names and details not disclosed; this figure is presented according to the annual report basis.
- In 2025, accounts receivable were RMB 5.147 billion, accounting for 16.3% of revenue, with estimated turnover of approximately 58 days; prepayments were RMB 1.057 billion and inventory was RMB 2.878 billion, and operating cash flow was also driven by licensing upfront payments.
| Year | Gross Margin | Net Margin | Reason for Change |
|---|---|---|---|
| 2022 | 83.61% | 18.36% | Jointly affected by traditional product pricing, innovative product mix, and cost structure. |
| 2023 | 84.55% | 18.86% | Gross margin recovered, jointly affected by product mix and cost changes. |
| 2024 | 86.25% | 22.64% | Innovative drug sales growth and licensing cooperation revenue affected profitability. |
| 2025 | 86.21% | 24.38% | Manufacturing gross margin essentially flat, with licensing revenue structure raising consolidated gross margin. |
Hengrui sits between pharmaceutical R&D and manufacturing and the medical payment system, with innovative drug R&D and commercialization bringing relatively high gross margins; further profit improvement depends on innovative drug volume ramp-up, product mix optimization, and licensing cooperation realization, rather than simply expanding production.
2.4 Industry and Peer Comparison
In the stage of innovative drug commercialization and international expansion; innovative drug volume ramp-up and licensing revenue improve profits, while medical insurance and centralized procurement constrain pricing, and the translation of R&D outcomes determines growth sustainability.
| Company | Positioning | Comparable Data | Differences from the Company |
|---|---|---|---|
| BeiGene (688235) | Global oncology pharmaceutical company | 2025 revenue RMB 38.225 billion; gross margin approximately 87.61%; PE(TTM) 95.25x | Overseas revenue and global commercialization of single products are more prominent, with larger scale. |
| Junshi Biosciences (688180) | Innovative drug company represented by oncology immunotherapy drugs | 2025 revenue approximately RMB 2.462 billion; pharmaceutical manufacturing gross margin 82.19%; PE(TTM) loss, not applicable | Smaller scale and loss-making, negative PE is not comparable to usual earnings multiples. |
| RemeGen (688331) | Antibody, biologics, and innovative therapy company | 2025 revenue RMB 3.251 billion; overall gross margin approximately 87.3%; PE(TTM) 11.38x | Smaller scale, licensing and non-recurring profit affect valuation comparability. |
| Fosun Pharma (600196) | Integrated group of pharmaceuticals, devices, and healthcare services | 2025 revenue RMB 41.662 billion; overall gross margin 50.07%; PE(TTM) 18.92x | Diversified business structure differs, and overall gross margin is not suitable for direct comparison. |
Hengrui's advantages lie in relatively large-scale R&D investment, an approved innovative drug portfolio, and commercialization capabilities, with 2025 innovative drug sales growth and licensing revenue achieved; the shortcoming is that profit remains constrained by medical insurance, centralized procurement, and hospital access, and licensing revenue also has annual volatility. Peers differ in scale, business structure, and licensing revenue recognition basis, so valuations and gross margins cannot be simply compared across companies.
3. Financial Quality
3.1 Operating Performance
| Reporting Period | Operating Revenue | YoY | Net Profit Attributable to Parent | YoY | Non-Recurring YoY | Gross Margin |
|---|---|---|---|---|---|---|
| H1 2026 | RMB 15.456 billion | -1.94% | RMB 4.465 billion | +0.34% | -12.71% | 86.33% |
| 2025 | RMB 31.629 billion | +13.02% | RMB 7.711 billion | +21.69% | +20.00% | 86.21% |
| 2024 | RMB 27.985 billion | +22.63% | RMB 6.337 billion | +47.28% | +49.18% | 86.25% |
Operating revenue and net profit attributable to parent are presented according to official statements for the same period and explicit currency; adjusted earnings and statutory profit are compared separately.
H1 net profit attributable to parent rose slightly while non-recurring profit declined, indicating pressure on core business profit; in the corresponding single quarter, revenue, net profit attributable to parent, and non-recurring profit all weakened YoY, with the non-recurring decline widening to 35.37%.
3.2 Financial Health Check
| Metric | Value | Assessment | Explanation |
|---|---|---|---|
| Weighted ROE | 8.04% (H1 2026) | Average | Below full-year 2025 level of 14.26%, with H1 earnings return weakening. |
| Debt-to-Asset Ratio | 8.17% (2026 Interim Report) | Good | Low debt ratio, with a sound capital structure. |
| Operating Cash Flow Net Amount / Net Profit | 0.44x (H1 2026) | Watch | Below 1x, with relatively weak cash conversion of profit. |
| Inventory Turnover Days | 250.1 days (2026 Interim Report) | Watch | Extended from 218.5 days at end-2025. |
4. Valuation and Market Expectations
4.1 Valuation Level
| Metric | Current | Own History | Peer Comparison |
|---|---|---|---|
| PE(TTM) | 40.55x | 6th percentile over past 5.2 years (median 55.89x) | Median 18.92x (BeiGene 95.25, RemeGen 11.38, Fosun Pharma 18.92) |
| PB(MRQ) | 4.86x | 2nd percentile over past 5.2 years (median 6.87x) | Median 7.06x (BeiGene 11.51, Junshi Biosciences 6.16, RemeGen 7.97, Fosun Pharma 1.32) |
| PS(TTM) | 10x | 16th percentile over past 5.2 years (median 11.75x) | Median 8.88x (BeiGene 9.50, Junshi Biosciences 12.10, RemeGen 8.27, Fosun Pharma 1.51) |
| Dividend Yield | 0.42% | — | — |
Valuation multiples are calculated programmatically based on 2026-09-30 closing data (trailing twelve months basis); peer multiples are calculated on the same basis using 2026-09-30 closing data
Market-implied expectations: At the current 40.55x P/E, if investors require an 8% annualized return and value the company at 15x P/E after 10 years, EPS needs to grow approximately 19.3% annually (excluding dividends, relatively conservative); short-term institutional net profit forecasts differ in time horizon and basis from this long-term EPS growth rate, so they cannot be directly compared as higher or lower.
PE-TTM 40.55x, PB-MRQ 4.86x, and PS-TTM 10x stand at the 6th, 2nd, and 16th percentiles over the past 5.2 years, respectively, below their historical medians; however, the absolute PE is still not low. The price implies approximately 19.3% annual EPS growth over the next 10 years, while institutions give 2026–2028 net profit growth of 20.5%, 16.0%, and 19.6%, which differ in basis from the long-term EPS growth requirement; whether earnings recovery can be sustained is key to valuation support.
4.2 Consensus Expectations
| Year | Operating Revenue | Net Profit Attributable to Parent | Net Profit Growth | Earnings Per Share (EPS) |
|---|---|---|---|---|
| 2026E | RMB 35.009 billion | RMB 9.295 billion | +20.5% | RMB 1.40 |
| 2027E | RMB 39.773 billion | RMB 10.783 billion | +16.0% | RMB 1.63 |
| 2028E | RMB 45.853 billion | RMB 12.898 billion | +19.6% | RMB 1.94 |
East Money consensus of research reports over the past six months, as of 2026-10-04. Institutional research report details are available; number of analysts is counted separately: 2026E net profit 20, EPS 20; 2027E net profit 20, EPS 20; 2028E net profit 19, EPS 19
4.3 Institutional Views
The average target price from 10 institutions is RMB 69.05, with a range of RMB 50–87.42; the latest is CICC's RMB 62.75 on September 30, 2026.
| Institution | Rating | Date | Remarks |
|---|---|---|---|
| CICC | Outperform | 2026-09-30 | Target price RMB 62.75 |
| Huachuang Securities | Strong Buy | 2026-09-26 | Target price RMB 72.7 |
| Orient Securities | Buy | 2026-08-31 | Target price RMB 58.05 |
| SPDB International | Hold | 2026-08-24 | Target price RMB 50 |
| Huatai Securities | Buy | 2026-08-23 | Target price RMB 80.17 |
5. Catalysts and Recent Events
5.1 Key Upcoming Milestones
| Time | Event | Focus |
|---|---|---|
| 2026-10-28 | Scheduled disclosure of Q3 2026 report | Focus on whether revenue, non-recurring profit, and innovative drug growth in the first three quarters can continue. |
| 2026-12-27 | Second unlock milestone of the 2024 employee stock ownership plan | Based on the original shareholding, the unlock upper limit is approximately 3.66 million shares; the actual number depends on company and individual assessment conditions. |
5.2 Recent Important Events
- 2026-07-24 to 2026-09-11 Three innovative drug indications approved (positive): Camrelizumab combination regimen approved for first-line cervical cancer treatment; Recombrolimab added HER2-positive colorectal cancer indication; Hetrombopag added CTIT and pediatric ITP indications, with subsequent sales contribution still to be verified.
- 2026-09-12 to 2026-09-15 Progress in innovative drug R&D projects (positive): SHR-A2009 included in breakthrough therapy designation; SHR-2004 marketing application accepted, and the company disclosed that the Phase III study met the superiority endpoint. Neither has received marketing approval.
- 2026-08-20 Interim report shows innovative drug sales growth (neutral): H1 innovative drug sales revenue grew 16.38% YoY, and R&D investment grew 18.96% YoY; during the same period, the company disclosed 7 innovative achievements approved for marketing and 9 marketing applications accepted.
- 2026-08-20 to 2026-09-25 New round of buyback and employee stock ownership plan progressed (neutral): The company plans to repurchase RMB 1 billion to RMB 2 billion of A-shares for the employee stock ownership plan, and the shareholders' meeting has approved the relevant proposals; as of September 17, 335,000 shares had been repurchased for RMB 14.50355 million, with subsequent execution still to be observed.
6. Bull-Bear Divergence and Risks
6.1 Bull Case
- In 2025, innovative drug sales revenue grew 26.09%, and the company has 24 Class 1 innovative drugs approved for marketing, with the commercialized product portfolio still expanding.
- In H1 2026, innovative drug revenue grew 16.38%; new indications approved for Camrelizumab and others, if ramped up, can support subsequent revenue recovery.
6.2 Bear Case
- In H1 2026, non-recurring net profit declined 12.71% YoY, with the single-quarter decline widening to 35.37%, indicating pressure on core business profitability.
- Institutions expect 2026 net profit growth of 20.5%, but H1 revenue has already declined 1.94%, and full-year forecast realization depends on a clear H2 recovery.
- H1 operating cash flow net amount / net profit was only 0.44x, and inventory turnover days rose to 250.1 days, indicating relatively weak cash conversion of profit and inventory efficiency.
6.3 Other Risks
- Medical insurance negotiations, centralized procurement, and hospital access price pressure → innovative drug prices or selling expenses may come under pressure, weakening the profit contribution of high-gross-margin products.
- R&D project failure or marketing approval and overseas registration falling short of expectations → pipeline commercialization delayed, with revenue growth and valuation expectations under pressure.
- Top five customers account for 55.72% of sales, with customer details not disclosed → changes in major customer procurement or payment collection may amplify revenue and cash flow volatility.
7. Tracking Checklist
| Tracking Metric | Current | Bull Verification | Bear Verification |
|---|---|---|---|
| Q3 non-recurring profit trend | H1 YoY -12.71%; single quarter -35.37% | Q3 single-quarter non-recurring decline narrows significantly from -35.37% or turns positive | Q3 single-quarter non-recurring YoY decline remains below -35.37% |
| Innovative drug revenue growth | H1 2026 YoY +16.38% | Full-year maintains double-digit growth and newly approved indications begin contributing to sales | Growth falls to single digits or new indications fail to generate sales increment |
| Operating cash conversion and inventory | Cash flow/net profit 0.44x; inventory turnover 250.1 days | Cash flow/net profit rebounds to near 1x, turnover days decline toward 218.5 days | Cash flow/net profit remains below 0.5x and turnover days continue to rise |
| Licensing revenue share | 10.7% of revenue in 2025, with significant annual volatility | 2026 licensing revenue has sustained project realization and does not depend on a single recognition | Licensing revenue declines and innovative drug sales fail to make up for growth |
8. Share Price and Short-Term Outlook (Next Week, Scenario Analysis, for Reference Only)
⚠️ Risk Notice: The weights below are subjective scenario projections based on current technical and capital flow conditions, not statistical probabilities.
8.1 Technical Overview
The share price has moved above MA5, MA10, and MA20, the MACD histogram has expanded, and short-term momentum has strengthened; however, the close is near the upper Bollinger Band and RSI6 is relatively high, so whether it can break through RMB 47.39–47.50 with volume is key. On the downside, watch the moving average zone at RMB 44.81–45.55 first.
| Indicator | Value | Interpretation |
|---|---|---|
| MA5/10/20 | MA5 45.55 / MA10 45.02 / MA20 44.81 | Share price is above the short-term moving average cluster, and the moving averages serve as support references nearby. |
| MA60 | MA60 50.03 | The medium-term moving average is above the current price and serves as a resistance reference. |
| MACD Histogram | DIF -0.776 / DEA -1.332 / Histogram 1.112 | Histogram expanded, short-term momentum improved. |
| RSI6/RSI14 | RSI6 72.6 / RSI14 55.3 | Short-cycle is relatively hot, while RSI14 is in a neutral-to-strong zone. |
| Bollinger Upper/Middle/Lower Bands | Upper 47.50 / Middle 44.81 / Lower 42.12 | Close is near the upper band; watch whether it can break through effectively. |
8.2 Key Price Levels
| Level | Range | Explanation |
|---|---|---|
| Short-Term Resistance | RMB 47.39–47.50 | Corresponds to the recent 20-day high and the Bollinger upper band; after an effective breakout, watch MA60 at RMB 50.03. |
| First Support | RMB 44.81–45.55 | Corresponds to the MA20 to MA5 moving average cluster; after a breakdown, look back to the Bollinger lower band at RMB 42.12. |
| Strong Support | RMB 41.89–42.12 | Corresponds to the 52-week low and the Bollinger lower band; losing this would open downside space. |
8.3 One-Week Range Estimated from Historical Volatility
Using the 2026-09-30 price of RMB 47.20 as the baseline and the return distribution over the past 300 trading days (scaled to the current index-weighted daily volatility of approximately 2.1%, retaining this stock's own frequency of large gains and losses) to estimate the closing price range over the next 5 trading days:
| Coverage Probability | Price Range | Relative to Baseline |
|---|---|---|
| Approximately 68% | RMB 44.75–48.75 | -5.2%–+3.3% |
| Approximately 95% | RMB 42.79–51.07 | -9.3%–+8.2% |
This range only reflects the stock's recent volatility magnitude and does not include direction judgment; in the event of major announcements or a sharp market decline, actual movements may still exceed the range.
8.4 Next-Week Scenarios (Subjective Weights, Not Statistical Probabilities)
- Consolidation (relatively high weight, approximately 50%): If RMB 44.81 is held and RMB 47.50 is not effectively broken, expect consolidation between RMB 44.81 and 47.50. Based on historical volatility estimates, the probability of the closing price falling within this range after one week is approximately 50%.
- Weaker downside (medium weight, approximately 30%): If RMB 44.81 is broken with volume, the price may retest the support zone of RMB 41.89–42.12. Based on historical volatility estimates, the probability of the closing price falling within this range after one week is approximately 15%.
- Rebound and strengthening (relatively low weight, approximately 20%): If turnover remains elevated and RMB 47.50 is effectively broken, watch for extension toward MA60 at RMB 50.03. Based on historical volatility estimates, the probability of the closing price falling within this range after one week is approximately 30%.
Values in parentheses are subjective weights; probabilities at the end of sentences are inferred from the volatility ranges above and only reflect volatility magnitude, not direction judgment.
8.5 Capital and Liquidity
As of 2026-09-30, over the past 10 trading days, daily turnover was approximately RMB 1.528 billion–5.200 billion, with a turnover rate of approximately 0.55%–1.79%; on that day, turnover was RMB 5.235 billion and the turnover rate was 1.76%. As of 2026-08-19, the top ten tradable shareholders collectively held 55.32%, including controlling-related entities and E Fund, China Europe, and Yinhua fund products; shareholder data has a disclosure lag, and the structure may have changed. Recent trading activity has been relatively high, but trading depth will still change with turnover.
If daily turnover continuously expands to above RMB 5.2 billion and the close breaks above RMB 47.50, this can serve as a volume-price breakout confirmation signal.
The above scenario projections are based on 2026-09-30 closing data and historical prices and technical indicators; short-term share prices will also be disturbed by multiple factors such as news, capital flows, and the broader market environment. Technical indicators themselves have lag and limitations, do not constitute a guarantee of future actual movements, and do not constitute buy or sell recommendations. Please make independent judgments based on the latest market information and bear investment risks yourself.
Sources
- 恒瑞医药(600276)_公司公告_恒瑞医药:2025年年度报告新浪财经_新浪网
- 恒瑞医药(600276)_公司公告_恒瑞医药:2024年年度报告新浪财经_新浪网
- 百济神州(688235)_公司公告_百济神州:2025年年度报告新浪财经_新浪网
- 上海君实生物医药科技股份有限公司2025年年度报告
- 荣昌生物(688331)_公司公告_荣昌生物:2025年年度报告新浪财经_新浪网
- 复星医药(600196)_公司公告_复星医药:2025年年度报告摘要新浪财经_新浪网
- 恒瑞医药2026年半年度报告
- 恒瑞医药2025年年度报告
- 恒瑞医药2024年年度报告
- 恒瑞医药2023年年度报告
- 腾讯财经行情(2026-09-30)
- 东方财富F10 合并资产负债表(2026中报)
- 东方财富 F10 盈利预测
- 恒瑞医药:恒瑞医药2026年半年度报告
- 证券代码:600276 证券简称:恒瑞医药 公告编号:临2026-105
- 证券代码:600276 证券简称:恒瑞医药 公告编号:临2026-114
- 恒瑞医药(600276)_公司公告_恒瑞医药:关于获得药品注册批准的公告新浪财经_新浪网
- 恒瑞医药(600276)_公司公告_恒瑞医药:关于药物纳入突破性治疗品种名单的公告新浪财经_新浪网
- 恒瑞医药(600276)_公司公告_恒瑞医药:关于药品上市许可申请获受理的提示性公告新浪财经_新浪网
- 证券代码:600276 证券简称:恒瑞医药 公告编号:临 2026-130
- 证券代码:600276 证券简称:恒瑞医药 公告编号:临 2026-121
- 恒瑞医药(600276)_公司公告_恒瑞医药:2026年第一次临时股东会决议公告新浪财经_新浪网
- 东方财富 个股资金流向
- 东方财富 股东研究
This report is automatically retrieved, compiled, and generated by AI based on public channel information, with information as of the 2026-09-30 close. There may be timeliness differences, and specific data should be based on the company's official announcements and authoritative data terminals. This report is only for information compilation and research reference, does not constitute any investment advice, and investors should make independent judgments and bear investment risks themselves.
Model value range, DCF / industry models, comparable-company checks, confidence and key assumptions
- Price
- HK$301.00
- Low
- HK$313.08
- Base
- HK$433.53
- High
- HK$566.80